News

The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…

Monocytes, a type of white blood cell, that carry a protein called CD206 are found at abnormally high levels in the blood of people with active ANCA-associated vasculitis (AAV), a study has found. This held true even when researchers compared people with AAV who had glomerulonephritis, a condition in…

Patients with active ANCA-associated vasculitis (AAV) can be distinguished from those who are in remission by the presence of different subsets of a type of immune cell known as regulatory T-cells, or Tregs, a new study reported. Reduced functionality of these regulatory immune cells had been previously implicated in…

People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…

Intensive care stays are more likely if oxygen-carrying hemoglobin levels are low at hospital admission in adults with kidney disease caused by ANCA-associated vasculitis (AAV), an analysis of medical records found. Severe kidney injury was the primary reason for intensive care unit (ICU) admission in these patients and associated…

In the year before being diagnosed with ANCA-associated vasculitis (AAV), Medicare beneficiaries had significantly higher use and costs of healthcare than those without AAV, an analysis found. According to researchers, earlier identification of AAV is necessary to provide patients with appropriate care and potentially reduce costs and healthcare use.

A reinforced pneumonia (pneumococcal) vaccination scheme, where one of the two vaccine types available is given at higher doses than usual, appears to be safe and may help people with ANCA-associated vasculitis (AAV) who are on rituximab to build better immunity against pneumococcal disease. These are the findings of…

Two cases of teen boys with ANCA-associated vasculitis (AAV) that caused heart problems — a very rare manifestation of the autoimmune disease — were described in a recent report. AAV-related heart issues may contribute to serious health concerns such as stroke, so it is important to screen for these…

Nasal Staphylococcus aureus infections don’t appear to influence disease activity in ANCA-associated vasculitis (AAV) patients with ear, nose, and throat involvement, a study suggests. Treatment with antibiotics to clear S. aureus infections didn’t reduce disease activity either. “Our study shows no difference in systemic and local disease activity between…

An 87-year-old man with ANCA-associated vasculitis (AAV), kidney disease and cutaneous squamous cell carcinoma (cSSC) — a type of skin cancer — partially responded to cemiplimab treatment without developing kidney complications or immune-related side effects. However, his response to cemiplimab was delayed as the tumor initially grew,  but regressed…